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Abstract: Recent investigations have focused on food-derived peptides as novel natural inhibitors
of dipeptidyl peptidase IV (DPP-IV), a new target for diabetes. This study aimed to optimize fast,
sensitive, and cost-effective DPP-IV assays in situ on human intestinal Caco-2 cells and ex vivo
on human serum. Both assays were applied to investigate the inhibitory activity of soy and lupin
peptides. The best conditions for in situ DPP-IV activity in Caco-2 cells were obtained using 2-day
cells and 50 µM Gly-Pro-AMC. Sitagliptin, used as reference inhibitor, showed a dose-dependent
response with a 50% inhibition concentration (IC50) of 0.6 µM. A lower IC50 (0.2 µM) was obtained
for sitagliptin on human serum incubated with the substrate for 24 h. Both assays were applied
to assess the activity of Lup1 (LTFPGSAED) and Soy1 (IAVPTGVA) on DPP-IV. Lup1 and Soy1
inhibited DPP-IV in situ, with IC50 values of of 207.5 and 223.2 µM, respectively, and maintained
their inhibitory activity ex vivo on circulating DPP-IV with a slightly lower potency. These assays can
be used to characterize the DPP-IV inhibitory activity of food-derived molecules more accurately
than in vitro biochemical tests. This combined approach also considers their effects on the circulating
form of DPP-IV, correlated to metabolic diseases.
Keywords: anti-diabetic activity; bioactive peptides; dipeptidyl peptidase IV; glucose
metabolism; sitagliptin
1. Introduction
Dipeptidyl peptidase IV (DPP-IV)/CD26 is a cell surface ectoenzyme (EC 3.4.14.5) that cleaves
dipeptides from the N-terminus of polypeptides in which proline is at the penultimate position.
DPP-IV, originally characterized as a T-cell differentiation antigen, was later reported to be ubiquitously
expressed on the surface of various cell types, such as renal proximal tubules, intestinal epithelial cells,
vascular endothelium, biliary caniliculi, alveolar pneumocytes, and skin fibroblasts [1]. A cleaved
form of the enzyme, possessing similar activity, is also found in serum, released from the membrane
by specific proteolytic cleavage to produce the soluble form. Enhanced soluble DPP-IV levels and/or
activity have been suggested to be a novel regulator of many metabolic diseases, such as type 2 diabetes
(T2DM), obesity, cardiovascular disease, and non-alcoholic fatty liver disease [2,3]. The importance of
DPP-IV as a promising therapeutic target for glycemic control has recently emerged [4]. It plays a major
role in glucose metabolism by N-terminal truncation and inactivation of the incretins glucagon-like
peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP). Together, GIP and GLP-1 stimulate
insulin biosynthesis at the pancreatic level and are responsible for up to 70% of insulin secretion
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following a meal [5]. However, they are rapidly inactivated by DPP-IV action [6]. Inhibition of DPP-IV
has been shown to promote insulin secretion and suppress glucagon release by prolonging the half-life
of GLP-1 and GIP [6,7]. Oral administration of synthetic DPP-IV inhibitors to type 2 diabetic patients
effectively reduces glycated hemoglobin levels [7]. The synthetic DPP-IV inhibitors currently in use
have very few side effects, but their long-term safety remains unknown [8]. Several food-derived
peptides have been characterized for their anti-diabetic activity [9,10] and many of them have been
identified and found to act as promising DPP-IV inhibitors, potentially contributing to glycemic
control [11–14].
However, in most of these studies, DPP-IV inhibitory activity has been evaluated only in silico
or with in vitro assays. Indeed, a careful literature analysis has highlighted that the main approach
for identifying food-derived peptides with DPP-IV inhibitory activity is the use of biochemical tools
involving purified porcine or human DPP-IV enzymes and a standard substrate. These tests have
the advantages of commercial application and the ability to screen a large number of samples in a
relatively short time, but also the disadvantage of providing an insufficient characterization of their
activity before performing expensive in vivo experimental studies. The development of specific in situ
cell-based assays and ex vivo tools would fill the gap between the biochemical and in vivo studies.
As DPP-IV is abundantly expressed on the luminal surface of enterocytes, any potential inhibitor
deriving from food digestion is likely to first interact with intestinal DPP-IV and other intestinal
peptidases before being absorbed, possibly being further metabolized, and released into circulation,
where it can interact with soluble and vascular endothelial DPP-IV, thus affecting circulating GIP
and GLP-1 levels. Thus, an intestinal cellular assay for DPP-IV inhibitory activities would be more
advantageous, compared to an in vitro test, to assay the enzyme in its natural environment and to
account for possible metabolic and transport effects.
The human intestinal Caco-2 cell line is the best currently available and most widely used model of
human intestinal enterocytes. From the time the cells reach confluence, they progressively differentiate
within 14 to 21 days, expressing morphological and functional characteristics of mature absorptive
enterocytes [15]. Several intestinal enzymes involved in food digestion are expressed on the surface of
Caco-2 cells, including DPP-IV [16,17].
It is also important to underline that a soluble form of DPP-IV lacking the cytoplasmic and
transmembrane domains is present in plasma and other body fluids [18] and that emerging evidences
suggest a potential role for this circulating peptidase in the pathophysiology of metabolic and
cardiovascular diseases [19]. In order to provide relevant information regarding the stability and
ability of absorbed food-derived peptides, it would be certainly useful to develop a suitable ex vivo
experiment on circulating DPP-IV using human serum samples.
Considering all of these observations, in order to evaluate the effect of food-derived peptides on
circulating DPP-IV activity, ex vivo experiments were also developed in the present work using human
serum samples. The aims of this study were: (1) to develop fast, sensitive, and accurate DPP-IV assays
either in situ on human intestinal cells or ex vivo on human serum, using a fluorescent substrate and
the specific DPP-IV inhibitor sitagliptin, and (2) to validate the assay on previously identified soy and
lupin peptides with known DPP-IV inhibitory activity. In particular, two peptides were chosen: one
deriving from lupin beta-conglutin precursor, Lup1 (LTFPGSAED), also named P7 [20,21], and the
second from soy glycinin, Soy1 (IAVPTGVA) [12].
2. Materials and Methods
2.1. Chemicals
Dulbecco’s modified Eagle medium (DMEM) was obtained from GIBCO (Thermo Fisher
Scientific, Waltham, MA USA). Fetal bovine serum (FBS) was from Hyclone Laboratories (Logan,
UT, USA). Stable L-glutamine, 1% non-essential amino acids, penicillin/streptomycin, and PBS
were from Euroclone (Milan, Italy). Sitagliptin and Gly-Pro-amido-4-methylcoumarin hydrobromide
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(Gly-Pro-AMC) were from Sigma-Aldrich (St. Louis, MO, USA). Polycarbonate filters, 12 mm in
diameter, 0.4 m in pore diameter, were from Transwell Corning Inc. (Lowell, MA, USA). Peptides Lup1
(LTFPGSAED) and Soy1 (IAVPTGVA) were synthetized by the company PRIMM (Milan, Italy) at >95%
purity. Human serum was freshly collected from a healthy female volunteer.
2.2. Cell Culture
Caco-2 cells, obtained from INSERM (Paris, France), were routinely sub-cultured at 50%
density [22] and maintained at 37 ◦C in a 90% air/10% CO2 atmosphere in DMEM containing 25 mM
of glucose, 3.7 g/L of NaHCO3, 4 mM of stable L-glutamine, 1% nonessential amino acids, 100 U/L of
penicillin, and 100 µg/L of streptomycin (complete medium), supplemented with 10% heat-inactivated
fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT, USA).
2.3. In Situ Cell-Based DPP-IV Activity Assay Optimization
For the experiments, cells were seeded on black 96-well plates with clear bottoms at a density
of 5 × 104 cells/well. The medium was regularly changed three times a week. Caco-2 cells DPP-IV
activity was assayed on days 2, 4, and 6 from seeding. On the day of the experiment, cells were
washed once with 100 µL of PBS without Ca++ and Mg++. Then, 100 µL of Gly-Pro-AMC substrate
at concentrations of 25, 50, 100, 200, and 400 µM in PBS without Ca++ and Mg++ were added and the
fluorescence signals (excitation/emission wavelengths 350/450 nm) in each well were measured using
a Synergy H1 (BioTek Instruments, Winooski, VT, USA) every 1 min, for up to 10 min.
2.4. In Situ Evaluation of the Inhibitory Effect of Sitagliptin, Lup1, and Soy1 on In Situ DPP-IV Activity
A total of 5×104 Caco-2 cells/well were seeded in black 96-well plates with clear bottoms.
The second day after seeding, spent media was discarded and the cells were treated with 100 µL
of sitagliptin (from 10−8 to 10−4 M), Lup1 and Soy1 (from 10−6 to 10−2.5 M), or vehicle in growth
medium for 1 h at 37 ◦C. Afterwards, treatments were removed and Caco-2 cells were washed once
with 100 µL of PBS without Ca++ and Mg++, before the addition to each well of 100 µL of Gly-Pro-AMC
substrate at the concentration of 50.0 µM in PBS without Ca++ and Mg++. Fluorescence signals (ex./em.
350/450 nm) were recorded using a Synergy H1 microplate reader every 1 min for up to 10 min.
2.5. Ex Vivo DPP-IV Activity Assay
Human serum samples prepared from freshly collected venous blood from a healthy female
volunteer were aliquoted 40 µL/well in black 96-well plates and 10 µL of each inhibitor were added
for 24 h at 37 ◦C. The inhibitors tested were sitagliptin (from 10−9 to 10−3 M), Lup1 and Soy1 (10, 100,
and 300 µM). Subsequently, 50 µL of 100 µM Gly-Pro-AMC was added to each well to achieve a final
substrate concentration of 50 µM. Fluorescence signals (ex./em. 350/450 nm) were then recorded
using a Synergy H1 microplate reader every 1 min for up to 10 min.
2.6. Statistical Analysis
Statistical analyses were carried out by one-way ANOVA (Graphpad Prism 7, GraphPad Software,
La Jolla, CA, USA) followed by Dunnett’s test. Values were expressed as means ± SD; p-values < 0.05
were considered to be significant.
3. Results
3.1. Development and Optimization of a Caco-2 Cell-Based DPP-IV Assay
In order to develop and optimize the experimental conditions for the in situ Caco-2 cell-based
DPP-IV activity assay, two parameters were considered: cell time in culture and DPP-IV substrate
concentration. DPP-IV is an enzyme also expressed by non-differentiated Caco-2 cells, although it
increases during culture differentiation [16,17].
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Taking this into consideration, cells were seeded in 96-well plates at a high density (5 × 104
cells/well) to rapidly achieve confluence and they were then cultured for 2, 4, and 6 days. Gly-Pro-AMC
was selected as the specific fluorescent substrate for DPP-IV activity, since DPP-IV selectively
metabolizes this substrate, releasing the AMC fluorophore, which emits fluorescence signals at 450 nm
upon excitation at 350 nm. DPP-IV activity was tested after 2, 4, and 6 days old Caco-2 cells cultures,
using 50 µM Gly-Pro-AMC in PBS, and the fluorescence signal was monitored up to 10 min. Figure 1a
shows that the detected relative fluorescence units (RFUs) steadily increased as a function of time,
reaching an overflow of the fluorescent signal at different times depending on the level of DPP-IV
activity at each age of the cells. Subsequently, DPP-IV activity was tested as a function of substrate
concentration (from 25 to 400 µM), using an appropriate time interval to be in the linear portion of the
enzyme activity, avoiding signal overflow.
Figure 1. In situ DPP-IV activity on 2-, 4-, and 6-day Caco-2 cells: (a) using 50 µM Gly-Pro-AMC
as a substrate, the fluorescence signal increased as a function of time and was linear at all cell ages
over the first 3 min. (b) The fluorescence signal was measured after 3 min as a function of substrate
Gly-Pro-AMC concentration at all cell ages. Data are the means ± SD of three experiments performed
in triplicate.
Figure 1b shows the detected RFUs after 3 min, for all cell ages at each tested substrate
concentration. The results indicate that DPP-IV activities expressed by cells after 2 and 4 days of
culture are similar, whereas a marked increase in activity was observed in cells after 6 days of culture.
RFU values obtained after 6 days were in fact higher than those measured after 2 and 4 days at all
tested substrate concentrations. Fluorescence steadily increased with Gly-Pro-AMC concentration,
reaching a plateau at 200 µM in cells of all ages.
Considering that cells aged 2 and 4 days are equivalent, and since the cells were certainly not
differentiated, whereas at 6 days the differentiation started giving non-reproducible responses, it was
decided to continue the experimentation using 2-day Caco-2 cell cultures and a concentration of 50 µM
Gly-Pro-AMC as the optimal parameters. This saved time and money.
3.2. Sitagliptin Inhibits DPP-IV Activity in Caco-2 Cells
Sitagliptin is a known synthetic DPP-IV inhibitor that was used as a reference compound for
the validation of the Caco-2 cell-based DPP-IV activity assay. Figure 2 shows the inhibitory effect of
DPP-IV activity by sitagliptin in situ. In detail, Caco-2 cells after 2 days of culture were treated for 1
h with sitagliptin at the fixed concentration of 1 µM, the Gly-Pro-AMC (50 µM) was added and the
fluorescence signals were measured for 10 min. The increase of the fluorescence signals, corresponding
to DPP-IV activity, was reduced by over 50% in the presence 1.0 µM sitagliptin compared to the control
(Figure 2a). To obtain information on the efficiency of DPP-IV inhibition, sitagliptin concentrations
ranging from 10−8 to 10−4 M were tested. The results indicated that sitagliptin inhibited DPP-IV
activity in 2-day Caco-2 cells in a dose-dependent manner, displaying a 50% inhibitory concentration
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(IC50) value of 0.6 µM (Figure 2b). Similar experiments were performed in 4- and 6-day Caco-2 cells:
the IC50 values at 4 and 6 days were 0.4 and 0.65 µM, respectively (Figure S1).
Figure 2. Inhibitory activity of sitagliptin on DPP-IV activity measured in situ on 2-day Caco-2 cells:
(a) at 1 µM, sitagliptin inhibited DPP-IV activity in Caco-2 cells by over 50%; (b) sitagliptin inhibited
DPP-IV activity in a dose-response manner, exhibiting an IC50 of 0.6 µM. Data are the means ± SD of
three experiments performed in triplicate.
3.3. Peptides Lup1 and Soy1 Inhibit DPP-IV Activity Expressed in Caco-2 Cells
Lup1 and Soy1 have previously been shown to exhibit DPP-IV inhibitory activity by an
in vitro assay, using a purified human recombinant enzyme with IC50 values of 228.0 and 106.0 µM,
respectively [12]. The validated Caco-2 cell-based DPP-IV activity assay was used to test the effects of
both peptides on DPP-IV activity in situ. Initially, Caco-2 cells were treated with Lup1 and Soy1 at
the fixed concentration of 100 µM for 1 h, then Gly-Pro-AMC substrate was added and the reaction
mixture was incubated for 10 min, during which the fluorescent signal was monitored every 1 min.
The results indicated that during the incubation time, a linear increase of RFU values was observed,
corresponding to the in situ DPP-IV activity. This in situ DPP-IV activity was reduced by 50% after
1 h of pre-incubation with both peptides as compared to the control samples (Figure 3a). Afterwards,
in order to calculate the IC50 values, Lup1 and Soy1 concentrations ranging from 10−6 to 10−2.5 M
were tested. Both peptides inhibited the DPP-IV activity in Caco-2 cells in a dose-dependent manner,
displaying IC50 values of 207.5 and 223.2 µM, respectively (Figure 3b).
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Figure 3. Inhibition of in situ DPP-IV activity by Lup1 and Soy1: (a) after pre-incubation (1 h) with
100 µM Lup1 and Soy1, DPP-IV activity was inhibited by 50% by both peptides; (b) measuring
inhibitory activity as a function of peptide concentration, a dose-dependent response was observed
with IC50 values of 207.5 µM for Lup1 and 223.2 µM for Soy1. Data are the means ± SD of three
experiments performed in triplicate. *: p > 0.05; **: p > 0.01.
3.4. Circulating DPP-IV Inhibition by Peptides Lup1 and Soy1
In order to develop a method to evaluate the effect of peptides Lup1 and Soy1 on circulating
DPP-IV activity, ex vivo experiments were performed using human serum samples and sitagliptin as a
reference inhibitor. In detail, human serum was incubated for 24 h with different concentrations of
sitagliptin ranging from 10−9 to 10−3 M. At the end of the incubation time, the substrate was added
and the fluorescence measured. Figure 4a shows that sitagliptin is able to inhibit circulating DPP-IV
activity in a dose-dependent manner with an IC50 of 0.2 µM. Similarly, the peptides Lup1 and Soy1
were incubated with serum samples at 100.0 and 300.0 µM, respectively, for 24 h at 37 ◦C, to assess
their activity on circulating serum DPP-IV. The findings clearly suggested that both peptides maintain
their ability to inhibit the DPP-IV activity ex vivo (Figure 4b). Specifically, peptide Lup1 decreased
the DPP-IV activity in the serum by 18.1% and 24.7%, whereas Soy1 reduced the circulating enzyme
activity by 27.7% and 35.0% at 100.0 and 300.0 µM concentrations, respectively, versus the control
samples (Figure 4b).
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Figure 4. Ex vivo assay of circulating DPP-IV in human serum: (a) sitagliptin showed a dose-dependent
inhibition of circulating DPP-IV with an IC50 of 0.2 µM; (b) Lup1 inhibited circulating DPP-IV activity
by 18.1% and 24.7% at 100 µM and 300 µM, respectively. Soy1, at the same concentrations, showed a
slightly higher inhibitory activity of 27.7% and 35.0%, respectively. Data are the means ± SD of three
experiments performed in triplicate. *: p > 0.05.
4. Discussion
4.1. Development and Validation of a Cell-Based DPP-IV Activity Assay Using Human Intestinal Caco-2 Cells
and an Ex Vivo Assay on Circulating DPP-IV Activity in Human Serum
In order to screen and identify novel food-derived DPP-IV inhibitors, the exclusive use of
biochemical tools represents a major limitation for the lack of several factors that might influence
their activity [23]. Moreover, since in vivo evidence of their potential activity as DPP-IV inhibitors
is scarce, the development of an alternative and cost-effective strategy is needed. For this reason,
the optimization of a cell-based DPP-IV activity assay represents an important target to fill this
relevant gap. Human Caco-2 cells represent an appropriate intestinal cell culture model expressing
several morphological and functional features of small intestinal enterocytes [15]. Furthermore, Caco-2
cells express good levels of DPP-IV mRNAs, which translate to active DPP-IV protein levels on
the Caco-2 apical cell membrane [16,17], facing the intestinal lumen. From a physiological point
of view, the intestinal epithelial cell layer is the first major barrier to absorption encountered by
food-derived bioactive peptides. In particular, the protease activities, located both on the enterocyte
surface and intracellularly, may affect the stability and integrity of food-derived peptides, which could
be degraded and/or modified, affecting either their transport across the intestinal epithelium or
their biological activity. Based on all of these considerations, the evaluation of the DPP-IV inhibitory
activity of food-derived peptides on the intestinal cells has additional advantages, compared to the
traditionally-used in vitro assay on the purified enzyme, as it mimics the intestinal environment as
well as its transport and metabolic activities. Apically-expressed enzyme activities can reliably and
efficiently be measured in live Caco-2 cells differentiated on filter inserts [24].
A similar cell-based assay has been recently proposed by other authors to evaluate DPP-IV activity
in living 7-day-differentiated Caco-2 cells [23]. Our method is more sensitive and cost-effective, since
here undifferentiated 2-day Caco-2 cells are used and a much lower concentration of the substrate
Gly-Pro-AMC is employed with respect to the previous method (50 µM versus 1 mM) [23]. Since the
fluorescent substrate concentration and level of enzyme expressed as a function of cell culture age are
tightly connected, the optimized conditions here proposed are a good compromise to save time and
money. In addition, a reference inhibitor of DPP-IV, sitagliptin, was used to validate the specificity of
the in situ assay. Interestingly, the IC50 values of sitagliptin were found to be similar in Caco-2 cells
after 2, 4, and 6 days, indicating that the characteristics of the enzyme in Caco-2 cells do not change as
a function of time in culture, thus justifying the use of undifferentiated 2-day Caco-2 cells.
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As mentioned in the introduction, besides the DPP-IV expressed on the cellular membranes,
the soluble form of this enzyme is also positively associated with the development of metabolic
diseases. For this reason, the soluble form of DPP-IV is also an important target for the management
of type 2 diabetes (T2DM). In this context, it is not so obvious that, after digestion and absorption,
food-derived peptides might retain their ability to also inhibit the circulating DPP-IV target. For this
reason, another assay was developed and validated to assess ex vivo the inhibitory activity on the
circulating form of DPP-IV using human serum. Again, the reference inhibitor sitagliptin was used
to validate this ex vivo assay, because it is known that this drug is rapidly absorbed in vivo and acts
on circulating and endothelial-expressed DPP-IV [25]. The ex vivo IC50 of sitagliptin was of the same
order of magnitude of the value obtained in the in situ assay, both in the lower µmolar range. The fact
that this ex vivo approach can also be applied to investigate the activity of a DPP-IV inhibitor has an
important physiological relevance, since circulating DPP-IV is mainly responsible for the degradation
of glucagon-like peptide-1(GLP-1) and GIP incretins, regulating plasma glucose levels [3,26].
As indicated in the introduction, the exclusive usage of the biochemical screening represents a
main limitation of this very dynamic field. This relevant aspect should be carefully considering
while selecting the best food-derived peptides for further in vivo and clinical investigations.
The methodologies provided here may be useful to fill the gap between the biochemical assays
and in vivo studies.
4.2. Lup1 and Soy1 Inhibit DPP-IV Activity
DPP-IV inhibitors have emerged as a new class of oral antidiabetic agents [27], with excellent
therapeutic potentials in the management of T2DM [28–30]. Although synthetic drugs such as
sitagliptin and vildagliptin are successfully commercialized, in the last years relevant studies have
been focusing on food-derived peptides as novel natural DPP-IV inhibitors [31,32].
In this context, many of these food peptides and/or food-protein hydrolysates are mainly
screened and characterized using in vitro and in silico approaches. Recently, we identified two
lupin and soybean peptides with a DPP-IV inhibitory activity: in particular, using an in vitro DPP-IV
activity assay, peptides Lup1 and Soy1 were shown to be able to inhibit the enzyme activity with a
dose response behavior, displaying IC50 values of 228.0 and 106.0 µM, respectively [25]. Moreover,
a molecular docking analysis permitted the prediction of the key molecular interactions, which stabilize
the active conformations of Lup1 and Soy1 within the DPP-IV enzyme site.
However, in the field of food-derived peptides with DPP-IV inhibitory activity, an important
limitation derives from the prevalent use of biochemical techniques, in which only the purified DPP-IV
enzyme is used to screen and characterize their bioactivity. In fact, the in vitro enzymatic assays
do not account for several parameters that might influence peptide bioactivity, such as resistance to
digestive enzymes or peptide absorption. Thus, there is a need for an improved characterization of
the inhibitory property of food-derived peptides using assay models that take into account intestinal
environmental parameters that could modify peptide bioactivity, such as the proteolytic activity of the
brush border (BB).
Considered all of these aspects, using live intestinal Caco-2 cells, experiments were performed
to investigate in detail the ability of Lup1 and Soy1 to inhibit DPP-IV activity, in the presence of BB
proteolytic activity. Our findings clearly suggested that both peptides are able to reduce the enzyme
activity, maintaining the dose-response relation. Specifically, the calculated IC50 of Lup1 was in
agreement with that obtained with the in vitro assay, whereas that of Soy1 was 2-fold higher than
that obtained by the in vitro tool. These results underline the different behavior and stability of these
peptides in the presence of the complex intestinal environment, as we have previously reported [20,33],
and reflect the different DPP-IV inhibiting activities under intestinal-like conditions. In particular,
we have previously demonstrated that Lup1 peptide is absorbed intact by differentiated intestinal
Caco-2 cells and it is not degraded in the presence of apical proteases after 4 h of incubation [20], a
fact that can explain why it exhibited an IC50 that was in line with that obtained in vitro [12]. On the
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contrary, Soy1 is susceptible to the action of intestinal endopeptidases in Caco-2 cells, which results
in the production of breakdown fragments, such as IAVPT and AVPTGVA, already after 2 h of
incubation [33]. Thus, the reduced DPP-IV inhibitory activity of Soy1 detected by the cell-based
technique is likely to be due to its metabolic degradation in situ by the hydrolytic activity of BB
membrane peptidases. As already indicated above, the DPP-IV inhibitory properties of absorbed
food-derived peptides may act on the circulating form of this enzyme. The inhibitory activity of
Lup1 and Soy1 was therefore tested ex vivo on human serum, showing that both peptides retained
their activity on the circulating serum DPP-IV, although at a slightly lower potency than observed
in vitro [12] and in situ.
5. Conclusions
In conclusion, to the best of our knowledge, these are the first food-derived peptides extensively
investigated for their behavior on the cell membrane and circulating forms of DPP-IV. This experimental
approach, combining in situ and ex vivo DPP-IV assays, could be applied to study the inhibitory
potential of other food-derived peptides in a more realistic fashion, thus overcoming the use of more
expensive and less ethical in vivo approaches on experimental animals.
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s1, Figure S1: In 4- and 6-day Caco-2 cells, sitagliptin inhibits DPIV activity in a dose-response manner with IC50
values of 0.4 and 0.65 µM, respectively. Data are the means ± SD of three experiments performed in triplicate.
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Abbreviations
AMC amido-4-methylcoumarin hydrobromide
BB brush border
DMEM Dulbecco’s modified Eagle’s medium
DPP-IV dipeptidyl peptidase IV
FBS fetal bovine serum
GLP-1 glucagon-like peptide-1
GIP gastrointestinal insulinotropic peptide
IC50 50% inhibitory concentration
PBS phosphate-buffered saline
RFU relative fluorescence unit
T2DM type 2 diabetes
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